Clinical Trial · NCT02194452

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Overview

This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT imaging, may help find and diagnose brain tumors.

Sponsor

University of Iowa

Phase

N/A

Contacts

M. Sue O'Dorisio, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02194452

Drug / Compound

DOTATOC

Isotope(s):

Target(s):

SSTR2

Ligand Class: Peptides

Chelator: DOTA

Eligibility

Inclusion

Fresh frozen tumor, and/or paraffin block of biopsy or resected tumor is recommended, but not required to determine expression of somatostatin receptors in tumor by immunohistochemistry and/or quantitative polymerase chain reaction (qPCR)
Eligible subjects must be able and willing to undergo the procedures of the study
Electronic version of pre-surgery MRI must be available for co-registration purposes

Exclusion

Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin of body that would preclude obtaining an MRI as part of the initial study evaluation
Women who are pregnant or breastfeeding
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons
Presence of any additional medical condition such as inter-current illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance